TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.

被引：2
|
作者：
Van Cutsem, Eric
Benedetti, Fabio M.
Mizuguchi, Hirokazu
Mayer, Robert J.
Falcone, Alfredo
Garcia-Carbonero, Rocio
Tabernero, Josep
Sobrero, Alberto F.
Peeters, Marc
Zaniboni, Alberto
Yoshino, Takayuki
Shimada, Yasuhiro
Yamazaki, Kentaro
Komatsu, Yoshito
Hochster, Howard S.
Lenz, Heinz-Josef
Ben Tran
Ohtsu, Atsushi
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Azienda Osped Univ Pisana, Pisa, Italy
[5] Hosp Univ Virgen del Rocio, Seville, Spain
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] IRCCS AOU San Martino IST, Genoa, Italy
[8] Univ Antwerp Hosp, Edegem, Belgium
[9] Fdn Poliambulanza, Brescia, Italy
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Hokkaido Univ, Hosp Canc Ctr, Sapporo, Hokkaido, Japan
[14] Yale Canc Ctr, New Haven, CT USA
[15] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[16] Royal Melbourne Hosp, Melbourne, Vic, Australia
[17] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
638
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation.
    Suenaga, Mitsukuni
    Mashima, Tetsuo
    Kawata, Naomi
    Dan, Shingo
    Wakatsuki, Takeru
    Shinozaki, Eiji
    Ichimura, Takashi
    Ogura, Mariko
    Takahari, Daisuke
    Osumi, Hiroki
    Ota, Yumiko
    Chin, Keisho
    Seimiya, Hiroyuki
    Yamaguchi, Kensei
    Yamaguchi, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).
    Pereira, Allan Andresson Lima
    Lam, Michael
    Marie, Preeti Kanikarla
    Raghav, Kanwal Pratap Singh
    Morris, Van Karlyle
    Brown, Hiromi
    Windham, Justin
    Duose, Dzifa Yawa
    Overman, Michael J.
    Sanchez, Eduardo Vilar
    Wistuba, Ignacio Ivan
    Kipp, Peter
    Janku, Filip
    Sinha, Sudhir
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [34] Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
    Cann, Christopher G.
    LaPelusa, Michael Brian
    Cimino, Sarah
    Grieb, Brian
    Ciombor, Kristen Keon
    Agarwal, Rajiv
    Das, Satya
    Goff, Laura Williams
    Cardin, Dana Backlund
    Davis, Shemeka
    Berlin, Jordan
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 95 - 95
  • [35] Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial
    Pfeiffer, P.
    Yilmaz, M.
    Moller, S.
    Zitnjak, D.
    Maltha, L.
    Krogh, M.
    Winther, S.
    Petersen, L.
    Hejlersen, F.
    Thomsen, K.
    Qvortrup, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals
    Beatriz, Gonzalez-Astorga
    Cebrian Irene, Gonzalez
    Ma Teresa, Delgado Urena
    Veronica, Conde
    Carmen, Sanchez-Toro
    Javier, Garcia-Garcia
    Encarnacion, Gonzalez-Flores
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
    Yoshino, Takayuki
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Nishina, Tomohiro
    Komatsu, Yoshito
    Baba, Hideo
    Tsuji, Akihito
    Yamaguchi, Kensei
    Muro, Kei
    Sugimoto, Naotoshi
    Tsuji, Yasushi
    Moriwaki, Toshikazu
    Esaki, Taito
    Hamada, Chikuma
    Tanase, Takanori
    Ohtsu, Atsushi
    LANCET ONCOLOGY, 2012, 13 (10): : 993 - 1001
  • [38] Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
    Vitale, Pasquale
    Zanaletti, Nicoletta
    Famiglietti, Vincenzo
    De Falco, Vincenzo
    Cervantes, Andres
    Rosello, Susanna
    Fenocchio, Elisabetta
    Milanesio, Michela
    Lombardi, Pasquale
    Ciardiello, Davide
    Martini, Giulia
    Martinelli, Erika
    Ciardiello, Fortunato
    Troiani, Teresa
    Napolitano, Stefania
    CLINICAL COLORECTAL CANCER, 2021, 20 (03) : 227 - 235
  • [39] Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the ERMES clinical trial.
    Normanno, Nicola
    Barone, Carlo
    Maiello, Evaristo
    Di Costanzo, Francesco
    Cassata, Antonio
    Tamburini, Emiliano
    Tonini, Giuseppe
    Bordonaro, Roberto
    Rosati, Gerardo
    Zaniboni, Alberto
    Lonardi, Sara
    Ferrari, Daris
    Frassineti, Giovanni Luca
    Tamberi, Stefano
    Pisconti, Salvatore
    Di Fabio, Francesca
    Forgione, Laura
    Rachiglio, Anna Maria
    Pasquale, Raffaella
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503
    Masayoshi, Dazai
    Satoshi, Yuki
    Hiroshi, Nakatsumi
    Yasushi, Tsuji
    Yoshimitsu, Kobayashi
    Kazuteru, Hatanaka
    Hiroyuki, Okuda
    Ayumu, Hosokawa
    Koichi, Furukawa
    Kohei, Ogawa
    Shinya, Minami
    Atsushi, Ishiguro
    Takuya, Honda
    Tomoyuki, Ohta
    Kazunori, Eto
    Takashi, Kato
    Junta, Nakajima
    Takahide, Sasaki
    Michio, Nakamura
    Yoshiaki, Shindo
    Yuh, Sakata
    Yoshito, Komatsu
    ANNALS OF ONCOLOGY, 2017, 28
12345